

Appendix to slide34-84: The number of patients in each group and crude survival probabilities at 1, 5, and 10 years after transplantation.

Slide34. Survival after Transplants by Transplant Type, 1991-2020

	Years after the first transplantation	N	OS
Auto	At transplantation	36,739	
	1 year	27,994	84.0%
	5 years	13,055	62.2%
	10 years	5,104	51.1%
Allo	At transplantation	60,618	
	1 year	36,694	64.9%
	5 years	18,861	49.2%
	10 years	8,905	44.7%

Slide35. Survival after Transplants by Donor Type and Stem Cell Sources, 1991-2020

	Years after the first transplantation	N	OS
Rel-BM	At transplantation	11,948	
	1 year	8,577	73.8%
	5 years	5,597	58.5%
	10 years	3,439	54.6%
Rel-PB	At transplantation	11,929	
	1 year	6,615	60.9%
	5 years	2,791	41.9%
	10 years	1,195	36.4%
UR-BM	At transplantation	21,051	
	1 year	13,210	66.9%
	5 years	7,071	51.3%
	10 years	3,095	46.4%
UR-PB	At transplantation	962	
	1 year	557	72.5%
	5 years	68	55.1%
	10 years	3	45.0%
UR-CB	At transplantation	14,728	
	1 year	7,731	57.6%
	5 years	3,333	43.5%
	10 years	1,170	39.6%

Slide36. Survival after Transplants for Leukemia, 1991-2020

	Years after the first transplantation	N	OS
AML	At transplantation	24,083	
	1 year	14,273	63.6%
	5 years	6,839	45.8%
	10 years	3,082	41.2%
ALL	At transplantation	12,829	
	1 year	8,569	70.9%
	5 years	4,407	51.8%
	10 years	2,140	47.4%
ATL	At transplantation	2,693	
	1 year	1,152	46.0%
	5 years	485	31.1%
	10 years	166	25.9%
CML	At transplantation	3,723	
	1 year	2,547	71.1%
	5 years	1,759	59.0%
	10 years	1,111	55.0%
MDS	At transplantation	6,577	
	1 year	3,943	65.7%
	5 years	1,832	49.2%
	10 years	727	42.6%

Slide37. Survival after Transplants for Malignant Lymphoma and MM/PCD, 1991-2020

	Years after the first transplantation	N	OS
NHL	At transplantation	21,036	
	1 year	13,883	72.8%
	5 years	7,043	57.4%
	10 years	2,837	50.0%
HL	At transplantation	1,674	
	1 year	1,316	86.7%
	5 years	636	69.5%
	10 years	225	62.3%
Other lymphoma / type missing	At transplantation	609	
	1 year	364	69.4%
	5 years	196	52.5%
	10 years	109	43.9%
MM/PCD	At transplantation	11,342	
	1 year	9,312	92.4%
	5 years	3,507	64.4%
	10 years	841	41.3%

Slide38. Survival after Autologous Transplants for Acute Leukemia, 1991-2020 <Autologous>

	Years after the first transplantation	N	OS
AML : Age ≤ 15	At transplantation	235	
	1 year	204	86.8%
	5 years	145	64.2%
	10 years	110	61.5%
AML : Age ≥ 16	At transplantation	1,472	
	1 year	1,150	83.2%
	5 years	690	67.3%
	10 years	337	63.4%
ALL : Age ≤ 15	At transplantation	394	
	1 year	321	81.5%
	5 years	230	59.7%
	10 years	155	55.4%
ALL : Age ≥ 16	At transplantation	348	
	1 year	210	61.3%
	5 years	92	31.4%
	10 years	55	26.7%

Slide39. Survival after Autologous Transplants for Malignant Lymphoma, 1991-2020 <Autologous>

	Years after the first transplantation	N	OS
NHL : Age ≤ 15	At transplantation	223	
	1 year	172	78.3%
	5 years	138	70.8%
	10 years	100	70.2%
NHL : Age ≥ 16	At transplantation	15,526	
	1 year	11,060	79.2%
	5 years	5,455	62.2%
	10 years	2,086	53.1%
HL : Age ≤ 15	At transplantation	37	
	1 year	30	86.3%
	5 years	15	73.5%
	10 years	8	73.5%
HL : Age ≥ 16	At transplantation	1,476	
	1 year	1,191	89.3%
	5 years	577	72.2%
	10 years	200	64.7%

Slide40. Survival after Autologous Transplants for MM/PCD, 1991-2020 <Autologous> (Age≥16)

	Years after the first transplantation	N	OS
MM / PCD	At transplantation	11,011	
	1 year	9,149	93.7%
	5 years	3,440	65.6%
	10 years	807	41.9%

Slide41. Survival after Allogeneic Transplants for AML, 2011-2020 <Allogeneic> (Age≤15)

	Years after the first transplantation	N	OS
Rel-BM	At transplantation	172	
	1 year	117	72.5%
	5 years	39	56.5%
	10 years	3	55.0%
Rel-PB	At transplantation	86	
	1 year	58	73.7%
	5 years	15	53.4%
	10 years	1	34.9%
UR-BM	At transplantation	131	
	1 year	99	82.5%
	5 years	42	65.8%
	10 years	2	62.9%
UR-CB	At transplantation	276	
	1 year	207	81.2%
	5 years	82	60.0%
	10 years	7	57.2%

Slide42. Survival after Allogeneic Transplants for AML, 2011-2020 <Allogeneic> (Age≥16)

	Years after the first transplantation	N	OS
Rel-BM	At transplantation	650	
	1 year	449	73.6%
	5 years	178	54.1%
	10 years	9	48.0%
Rel-PB	At transplantation	2,622	
	1 year	1,427	62.8%
	5 years	385	41.5%
	10 years	11	35.2%
UR-BM	At transplantation	3,366	
	1 year	2,029	67.0%
	5 years	742	49.5%
	10 years	27	44.9%
UR-CB	At transplantation	4,051	
	1 year	2,037	57.3%
	5 years	544	41.5%
	10 years	17	35.4%

Slide43. Survival after Allogeneic Transplants for AML, 2011-2020 <HLA-identical Sibling> (Age≤15)

	Years after the first transplantation	N	OS
Standard risk	At transplantation	58	
	1 year	50	91.1%
	5 years	8	67.9%
	10 years	0	.
Advanced risk	At transplantation	31	
	1 year	16	55.8%
	5 years	6	38.4%
	10 years	0	.

Slide44. Survival after Allogeneic Transplants for AML, 2011-2020 <HLA-identical Sibling> (Age≥16)

	Years after the first transplantation	N	OS
Standard risk	At transplantation	1,262	
	1 year	951	83.3%
	5 years	343	61.0%
	10 years	15	55.9%
Advanced risk	At transplantation	670	
	1 year	280	46.2%
	5 years	69	26.0%
	10 years	1	19.8%

Slide45. Survival after Allogeneic Transplants for AML, 2011-2020 <UR-BM> (Age≤15)

	Years after the first transplantation	N	OS
Standard risk	At transplantation	89	
	1 year	77	94.1%
	5 years	35	80.2%
	10 years	2	76.4%
Advanced risk	At transplantation	42	
	1 year	22	58.2%
	5 years	7	36.2%
	10 years	0	.

Slide46. Survival after Allogeneic Transplants for AML, 2011-2020 <UR-BM> (Age≥16)

	Years after the first transplantation	N	OS
Standard risk	At transplantation	2,258	
	1 year	1,573	77.7%
	5 years	601	60.7%
	10 years	22	55.4%
Advanced risk	At transplantation	1,105	
	1 year	455	45.1%
	5 years	140	26.8%
	10 years	5	23.6%

Slide47. Survival after Allogeneic Transplants for AML, 2011-2020 <UR-CB> (Age≤15)

	Years after the first transplantation	N	OS
Standard risk	At transplantation	182	
	1 year	164	94.4%
	5 years	69	75.6%
	10 years	5	71.7%
Advanced risk	At transplantation	94	
	1 year	43	54.1%
	5 years	13	27.8%
	10 years	2	27.8%

Slide48. Survival after Allogeneic Transplants for AML, 2011-2020 <UR-CB> (Age≥16)

	Years after the first transplantation	N	OS
Standard risk	At transplantation	1,855	
	1 year	1,171	72.8%
	5 years	319	58.8%
	10 years	7	51.5%
Advanced risk	At transplantation	2,196	
	1 year	867	44.3%
	5 years	225	27.3%
	10 years	10	22.3%

Slide49. Survival after Allogeneic Transplants for ALL, 2011-2020 <Allogeneic> (Age≤15)

	Years after the first transplantation	N	OS
Rel-BM	At transplantation	216	
	1 year	170	82.5%
	5 years	72	66.9%
	10 years	4	61.6%
Rel-PB	At transplantation	117	
	1 year	58	59.3%
	5 years	23	42.7%
	10 years	0	.
UR-BM	At transplantation	245	
	1 year	194	84.9%
	5 years	85	71.1%
	10 years	3	68.0%
UR-CB	At transplantation	393	
	1 year	294	83.1%
	5 years	125	70.2%
	10 years	3	67.6%

Slide50. Survival after Allogeneic Transplants for ALL, 2011-2020 <Allogeneic> (Age≥16)

	Years after the first transplantation	N	OS
Rel-BM	At transplantation	366	
	1 year	289	84.0%
	5 years	113	66.3%
	10 years	6	63.8%
Rel-PB	At transplantation	988	
	1 year	674	77.7%
	5 years	170	55.6%
	10 years	4	50.6%
UR-BM	At transplantation	1,630	
	1 year	1,134	77.7%
	5 years	421	60.8%
	10 years	6	51.9%
UR-CB	At transplantation	1,208	
	1 year	749	71.0%
	5 years	236	55.2%
	10 years	7	50.5%

Slide51. Survival after Allogeneic Transplants for ALL, 2011-2020 <HLA-identical Sibling> (Age≤15)

	Years after the first transplantation	N	OS
Standard risk	At transplantation	61	
	1 year	57	96.7%
	5 years	31	90.8%
	10 years	1	87.5%
Advanced risk	At transplantation	68	
	1 year	48	78.3%
	5 years	12	52.2%
	10 years	1	52.2%

Slide52. Survival after Allogeneic Transplants for ALL, 2011-2020 <HLA-identical Sibling> (Age≥16)

	Years after the first transplantation	N	OS
Standard risk	At transplantation	725	
	1 year	595	90.0%
	5 years	210	71.5%
	10 years	8	69.1%
Advanced risk	At transplantation	194	
	1 year	116	65.6%
	5 years	25	39.6%
	10 years	1	31.2%

Slide53. Survival after Allogeneic Transplants for ALL, 2011-2020 <UR-BM> (Age≤15)

	Years after the first transplantation	N	OS
Standard risk	At transplantation	123	
	1 year	111	96.6%
	5 years	54	87.2%
	10 years	1	83.1%
Advanced risk	At transplantation	122	
	1 year	83	73.2%
	5 years	31	54.8%
	10 years	2	52.8%

Slide54. Survival after Allogeneic Transplants for ALL, 2011-2020 <UR-BM> (Age≥16)

	Years after the first transplantation	N	OS
Standard risk	At transplantation	1,233	
	1 year	935	83.8%
	5 years	368	68.9%
	10 years	5	57.9%
Advanced risk	At transplantation	396	
	1 year	199	58.2%
	5 years	53	34.4%
	10 years	1	32.2%

Slide55. Survival after Allogeneic Transplants for ALL, 2011-2020 <UR-CB> (Age≤15)

	Years after the first transplantation	N	OS
Standard risk	At transplantation	187	
	1 year	159	91.2%
	5 years	86	83.9%
	10 years	2	81.6%
Advanced risk	At transplantation	206	
	1 year	136	75.6%
	5 years	39	57.2%
	10 years	1	53.8%

Slide56. Survival after Allogeneic Transplants for ALL, 2011-2020 <UR-CB> (Age≥16)

	Years after the first transplantation	N	OS
Standard risk	At transplantation	777	
	1 year	551	81.3%
	5 years	191	68.9%
	10 years	5	61.6%
Advanced risk	At transplantation	429	
	1 year	196	52.4%
	5 years	44	30.0%
	10 years	2	30.0%

Slide57. Survival after Allogeneic Transplants for CML, 2011-2020 <Allogeneic> (Age≤15)

	Years after the first transplantation	N	OS
Rel-BM	At transplantation	16	
	1 year	12	75.0%
	5 years	9	75.0%
	10 years	1	75.0%
Rel-PB	At transplantation	2	
	1 year	2	100.0%
	5 years	1	100.0%
	10 years	1	100.0%
UR-BM	At transplantation	14	
	1 year	12	85.7%
	5 years	6	78.6%
	10 years	1	78.6%
UR-CB	At transplantation	8	
	1 year	7	100.0%
	5 years	3	100.0%
	10 years	1	100.0%

Slide58. Survival after Allogeneic Transplants for CML, 2011-2020 <Allogeneic> (Age≥16)

	Years after the first transplantation	N	OS
Rel-BM	At transplantation	38	
	1 year	31	91.7%
	5 years	13	74.4%
	10 years	1	67.0%
Rel-PB	At transplantation	151	
	1 year	103	79.0%
	5 years	30	63.7%
	10 years	0	.
UR-BM	At transplantation	259	
	1 year	174	77.4%
	5 years	68	66.1%
	10 years	2	59.2%
UR-CB	At transplantation	192	
	1 year	119	71.0%
	5 years	57	61.7%
	10 years	3	52.9%

Slide59. Survival after Allogeneic Transplants for CML, 2011-2020 <HLA-identical Sibling> (Age≥16)

	Years after the first transplantation	N	OS
Standard risk	At transplantation	45	
	1 year	34	95.0%
	5 years	16	89.1%
	10 years	0	.
Advanced risk	At transplantation	79	
	1 year	60	84.1%
	5 years	17	60.3%
	10 years	1	56.5%

Slide60. Survival after Allogeneic Transplants for CML, 2011-2020 <UR-BM> (Age≥16)

	Years after the first transplantation	N	OS
Standard risk	At transplantation	101	
	1 year	69	81.6%
	5 years	28	71.8%
	10 years	2	71.8%
Advanced risk	At transplantation	158	
	1 year	105	74.8%
	5 years	40	62.7%
	10 years	0	.

Slide61. Survival after Allogeneic Transplants for CML, 2011-2020 <UR-CB> (Age≥16)

	Years after the first transplantation	N	OS
Standard risk	At transplantation	52	
	1 year	31	82.5%
	5 years	16	79.8%
	10 years	0	.
Advanced risk	At transplantation	140	
	1 year	88	67.1%
	5 years	41	56.4%
	10 years	3	44.8%

Slide62. Survival after Allogeneic Transplants for MDS, 2011-2020 <Allogeneic> (Age≤15)

	Years after the first transplantation	N	OS
Rel-BM	At transplantation	69	
	1 year	56	91.1%
	5 years	31	91.1%
	10 years	1	88.0%
Rel-PB	At transplantation	13	
	1 year	7	91.7%
	5 years	3	76.4%
	10 years	0	.
UR-BM	At transplantation	109	
	1 year	86	93.4%
	5 years	37	85.0%
	10 years	2	85.0%
UR-CB	At transplantation	47	
	1 year	33	79.9%
	5 years	16	69.2%
	10 years	0	.

Slide63. Survival after Allogeneic Transplants for MDS, 2011-2020 <Allogeneic> (Age≥16)

	Years after the first transplantation	N	OS
Rel-BM	At transplantation	228	
	1 year	144	66.4%
	5 years	47	48.9%
	10 years	0	.
Rel-PB	At transplantation	662	
	1 year	363	65.5%
	5 years	89	48.5%
	10 years	1	44.5%
UR-BM	At transplantation	1,519	
	1 year	911	67.1%
	5 years	295	46.6%
	10 years	6	38.6%
UR-CB	At transplantation	1,060	
	1 year	546	59.8%
	5 years	145	42.8%
	10 years	3	31.6%

Slide64. Survival after Allogeneic Transplants for MDS, 2011-2020 <HLA-identical Sibling> (Age≤15)

	Years after the first transplantation	N	OS
Standard risk	At transplantation	45	
	1 year	38	91.0%
	5 years	21	91.0%
	10 years	0	.
Advanced risk	At transplantation	8	
	1 year	7	87.5%
	5 years	5	72.9%
	10 years	0	.

Slide65. Survival after Allogeneic Transplants for MDS, 2011-2020 <HLA-identical Sibling> (Age≥16)

	Years after the first transplantation	N	OS
Standard risk	At transplantation	198	
	1 year	139	76.1%
	5 years	48	64.0%
	10 years	1	64.0%
Advanced risk	At transplantation	336	
	1 year	191	63.3%
	5 years	58	44.4%
	10 years	0	.

Slide66. Survival after Allogeneic Transplants for MDS, 2011-2020 <UR-BM> (Age≤15)

	Years after the first transplantation	N	OS
Standard risk	At transplantation	78	
	1 year	68	97.4%
	5 years	31	91.3%
	10 years	1	91.3%
Advanced risk	At transplantation	27	
	1 year	16	88.9%
	5 years	6	76.2%
	10 years	1	76.2%

Slide67. Survival after Allogeneic Transplants for MDS, 2011-2020 <UR-BM> (Age≥16)

	Years after the first transplantation	N	OS
Standard risk	At transplantation	561	
	1 year	370	72.4%
	5 years	137	53.5%
	10 years	1	46.3%
Advanced risk	At transplantation	927	
	1 year	526	63.9%
	5 years	157	42.3%
	10 years	5	34.3%

Slide68. Survival after Allogeneic Transplants for MDS, 2011-2020 <UR-CB> (Age≤15)

	Years after the first transplantation	N	OS
Standard risk	At transplantation	21	
	1 year	15	81.0%
	5 years	9	73.6%
	10 years	0	.
Advanced risk	At transplantation	21	
	1 year	15	79.2%
	5 years	5	62.5%
	10 years	0	.

Slide69. Survival after Allogeneic Transplants for MDS, 2011-2020 <UR-CB> (Age≥16)

	Years after the first transplantation	N	OS
Standard risk	At transplantation	334	
	1 year	184	64.8%
	5 years	51	47.9%
	10 years	2	31.0%
Advanced risk	At transplantation	716	
	1 year	359	57.4%
	5 years	93	40.4%
	10 years	1	32.3%

Slide70. Survival after Allogeneic Transplants for NHL, 2011-2020 <Allogeneic> (Age≤15)

	Years after the first transplantation	N	OS
Rel-BM	At transplantation	26	
	1 year	17	72.0%
	5 years	7	72.0%
	10 years	1	72.0%
Rel-PB	At transplantation	19	
	1 year	9	52.6%
	5 years	3	36.1%
	10 years	0	.
UR-BM	At transplantation	33	
	1 year	18	67.3%
	5 years	6	55.9%
	10 years	0	.
UR-CB	At transplantation	45	
	1 year	28	72.0%
	5 years	10	72.0%
	10 years	0	.

Slide71. Survival after Allogeneic Transplants for NHL, 2011-2020 <Allogeneic> (Age≥16)

	Years after the first transplantation	N	OS
Rel-BM	At transplantation	137	
	1 year	81	61.5%
	5 years	35	51.7%
	10 years	6	51.7%
Rel-PB	At transplantation	766	
	1 year	322	48.9%
	5 years	105	37.7%
	10 years	2	31.8%
UR-BM	At transplantation	645	
	1 year	362	62.8%
	5 years	159	49.7%
	10 years	7	46.7%
UR-CB	At transplantation	900	
	1 year	391	48.5%
	5 years	150	39.0%
	10 years	1	36.9%

Slide72. Survival after Allogeneic Transplants for NHL, 2011-2020 <HLA-identical Sibling> (Age≥16)

	Years after the first transplantation	N	OS
1CR	At transplantation	103	
	1 year	78	83.8%
	5 years	31	67.3%
	10 years	4	60.1%
2CR	At transplantation	47	
	1 year	34	78.4%
	5 years	17	76.1%
	10 years	0	.
>=3CR	At transplantation	18	
	1 year	16	94.1%
	5 years	3	73.5%
	10 years	0	.
1PR	At transplantation	52	
	1 year	36	74.2%
	5 years	16	57.6%
	10 years	2	54.0%
2PR	At transplantation	58	
	1 year	32	61.3%
	5 years	15	52.7%
	10 years	1	52.7%
NIR	At transplantation	215	
	1 year	83	40.4%
	5 years	26	29.1%
	10 years	1	23.1%

Slide73. Survival after Allogeneic Transplants for NHL, 2011-2020 <UR-BM> (Age≤15)

	Years after the first transplantation	N	OS
1CR	At transplantation	6	
	1 year	6	100.0%
	5 years	0	.
	10 years	0	.
2CR	At transplantation	6	
	1 year	3	66.7%
	5 years	3	66.7%
	10 years	0	.
>=3CR	At transplantation	1	
	1 year	0	.
	5 years	0	.
	10 years	0	.
1PR	At transplantation	4	
	1 year	1	33.3%
	5 years	1	33.3%
	10 years	0	.
2PR	At transplantation	1	
	1 year	0	.
	5 years	0	.
	10 years	0	.
NIR	At transplantation	15	
	1 year	8	70.1%
	5 years	2	56.1%
	10 years	0	.

Slide74. Survival after Allogeneic Transplants for NHL, 2011-2020 <UR-BM> (Age≥16)

	Years after the first transplantation	N	OS
1CR	At transplantation	152	
	1 year	105	76.5%
	5 years	47	62.2%
	10 years	1	62.2%
2CR	At transplantation	75	
	1 year	55	83.0%
	5 years	23	65.9%
	10 years	0	.
>=3CR	At transplantation	43	
	1 year	28	69.1%
	5 years	16	60.6%
	10 years	1	60.6%
1PR	At transplantation	61	
	1 year	38	70.9%
	5 years	13	50.0%
	10 years	2	50.0%
2PR	At transplantation	71	
	1 year	40	65.9%
	5 years	21	53.3%
	10 years	1	53.3%
NIR	At transplantation	243	
	1 year	96	43.8%
	5 years	39	33.3%
	10 years	2	28.2%

**Slide75. Survival after Allogeneic Transplants for NHL,
2011-2020 <UR-CB> (Age≤15)**

	Years after the first transplantation	N	OS
1CR	At transplantation	13	
	1 year	9	76.2%
	5 years	4	76.2%
	10 years	0	.
2CR	At transplantation	5	
	1 year	4	100.0%
	5 years	1	100.0%
	10 years	0	.
>=3CR	At transplantation	2	
	1 year	2	100.0%
	5 years	1	100.0%
	10 years	0	.
2PR	At transplantation	6	
	1 year	5	83.3%
	5 years	0	.
	10 years	0	.
NIR	At transplantation	19	
	1 year	8	55.4%
	5 years	4	55.4%
	10 years	0	.

**Slide76. Survival after Allogeneic Transplants for NHL,
2011-2020 <UR-CB> (Age≥16)**

	Years after the first transplantation	N	OS
1CR	At transplantation	143	
	1 year	86	67.8%
	5 years	33	56.4%
	10 years	0	.
2CR	At transplantation	79	
	1 year	41	62.8%
	5 years	20	52.2%
	10 years	0	.
>=3CR	At transplantation	27	
	1 year	19	74.1%
	5 years	12	69.1%
	10 years	0	.
1PR	At transplantation	102	
	1 year	51	56.6%
	5 years	18	53.1%
	10 years	0	.
2PR	At transplantation	82	
	1 year	33	45.5%
	5 years	10	37.3%
	10 years	0	.
NIR	At transplantation	467	
	1 year	161	37.4%
	5 years	57	27.3%
	10 years	1	24.0%

**Slide77. Survival after Autologous Transplants for MM /
PCD, 2011-2020 <Autologous> (Age≥16)**

	Years after the first transplantation	N	OS
MM / PCD	At transplantation	7,167	
	1 year	5,819	95.3%
	5 years	1,655	72.3%
	10 years	32	52.7%

**Slide78. Survival after Allogeneic Transplants for MM /
PCD, 2011-2020 <Allogeneic> (Age≥16)**

	Years after the first transplantation	N	OS
Rel-BM	At transplantation	4	
	1 year	2	50.0%
	5 years	0	.
	10 years	0	.
Rel-PB	At transplantation	31	
	1 year	15	51.6%
	5 years	5	38.3%
	10 years	0	.
UR-BM	At transplantation	24	
	1 year	12	54.2%
	5 years	2	23.0%
	10 years	0	.
UR-CB	At transplantation	17	
	1 year	4	23.5%
	5 years	1	11.8%
	10 years	0	.

Slide79. Survival after Autologous Transplants for MM / PCD, 2011-2020 <Autologous> (Age≥16)

	Years after the first transplantation	N	OS
CR / sCR	At transplantation	1,459	
	1 year	1,187	97.9%
	5 years	285	78.7%
	10 years	5	58.2%
VGPR	At transplantation	2,200	
	1 year	1,788	96.6%
	5 years	508	73.0%
	10 years	8	49.0%
PR	At transplantation	2,508	
	1 year	2,070	95.0%
	5 years	634	69.9%
	10 years	12	50.3%
SD	At transplantation	229	
	1 year	183	91.2%
	5 years	50	55.2%
	10 years	3	50.1%
PD / Rel	At transplantation	161	
	1 year	95	67.2%
	5 years	15	28.3%
	10 years	0	.

Slide80. Survival after Allogeneic Transplants for MM / PCD, 2011-2020 <Allogeneic> (Age≥16)

	Years after the first transplantation	N	OS
CR / sCR	At transplantation	16	
	1 year	10	68.8%
	5 years	0	.
	10 years	0	.
VGPR	At transplantation	9	
	1 year	7	77.8%
	5 years	1	31.1%
	10 years	0	.
PR	At transplantation	21	
	1 year	10	52.4%
	5 years	6	31.4%
	10 years	0	.
SD	At transplantation	9	
	1 year	2	22.2%
	5 years	0	.
	10 years	0	.
PD / Rel	At transplantation	17	
	1 year	2	11.8%
	5 years	1	5.9%
	10 years	0	.

Slide81. Survival after Allogeneic Transplants for AA, 2011-2020 <Allogeneic> (Age≤15)

	Years after the first transplantation	N	OS
Rel-BM	At transplantation	136	
	1 year	117	97.0%
	5 years	56	96.1%
	10 years	2	96.1%
Rel-PB	At transplantation	7	
	1 year	5	71.4%
	5 years	3	71.4%
	10 years	0	.
UR-BM	At transplantation	137	
	1 year	112	95.3%
	5 years	55	92.8%
	10 years	4	92.8%
UR-CB	At transplantation	21	
	1 year	20	100.0%
	5 years	8	100.0%
	10 years	1	100.0%

Slide82. Survival after Allogeneic Transplants for AA, 2011-2020 <Allogeneic> (Age≥16)

	Years after the first transplantation	N	OS
Rel-BM	At transplantation	197	
	1 year	167	92.2%
	5 years	73	87.9%
	10 years	4	85.8%
Rel-PB	At transplantation	79	
	1 year	51	74.3%
	5 years	16	67.9%
	10 years	1	67.9%
UR-BM	At transplantation	274	
	1 year	204	81.0%
	5 years	87	74.3%
	10 years	4	74.3%
UR-CB	At transplantation	135	
	1 year	84	70.7%
	5 years	34	69.7%
	10 years	3	69.7%

**Slide83. Survival after Allogeneic Transplants for AA,
2011-2020 <Allogeneic> (Age≤15)**

	Years after the first transplantation	N	OS
HLA-identical Sibling	At transplantation	111	
	1 year	96	96.3%
	5 years	49	95.2%
	10 years	2	95.2%
UR-BM	At transplantation	137	
	1 year	112	95.3%
	5 years	55	92.8%
	10 years	4	92.8%
UR-CB	At transplantation	21	
	1 year	20	100.0%
	5 years	8	100.0%
	10 years	1	100.0%

**Slide84. Survival after Allogeneic Transplants for AA,
2011-2020 <Allogeneic> (Age≥16)**

	Years after the first transplantation	N	OS
HLA-identical Sibling	At transplantation	216	
	1 year	178	88.7%
	5 years	77	83.2%
	10 years	4	83.2%
UR-BM	At transplantation	274	
	1 year	204	81.0%
	5 years	87	74.3%
	10 years	4	74.3%
UR-CB	At transplantation	135	
	1 year	84	70.7%
	5 years	34	69.7%
	10 years	3	69.7%